Monday, July 23, 2012

Addition of Tarceva (erlotinib) to Nexavar (sorafenib) did not Provide Additional Benefit to Patients with Unresectable Liver Cancer Versus Nexavar alone in Phase 3 Trial

...continued
      

URL: http://www.investorpoint.com/news/INTHPINK/52914832/

Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)